New hope for rare heart condition: AGP100 drug trial begins
NCT ID NCT07263139
First seen Jan 08, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests a new drug, AGP100, in 10 adults with a rare inherited heart condition called CPVT, which causes dangerous fast heartbeats during stress or exercise. Participants take three different doses of AGP100 over six weeks while continuing their usual heart medications. The goal is to see if AGP100 is safe and helps maintain a normal heart rhythm during exercise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Cardiology, Oslo University Hospital
RECRUITINGOslo, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.